Travere Therapeutics, Inc. TVTX
51.56 USD -0.48 (-0.92%)
At closeNov 12, 2026, 4:00 PM EST
51.56 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
51.11 Day range 52.52
22.59 52-week range 68.73
- YTD
- +34.94%
- 1 year
- +41.38%
News
defenseworld.net Head-To-Head Survey: InflaRx (NASDAQ:IFRX) vs. Travere Therapeutics (NASDAQ:TVTX) Travere Therapeutics (NASDAQ: TVTX - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
benzinga.com Leerink Partners Maintains Outperform on Travere Therapeutics, Lowers Price Target to $67 Leerink Partners analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and lowers the price target from $78 to $67.- benzinga.com Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $72 Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $72.
benzinga.com Guggenheim Maintains Buy on Travere Therapeutics, Lowers Price Target to $78 Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $89 to $78.
benzinga.com Travere Therapeutics Q3 2026 Earnings Call Transcript Travere Therapeutics (NASDAQ:TVTX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com Travere Therapeutics Q3 Adj. EPS $(0.31) Misses $(0.06) Estimate, Sales $224.563M Beat $195.292M Estimate Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.06) by 416.67 percent. This is a 152.54 percent decrease over…- benzinga.com Reported Friday, Travere Says PROTECT Biomarker Data Add To Superior Proteinuria Reduction, Slower Kidney Function Decline Versus Irbesartan, Supporting FILSPARI As Non-Immunosuppressive, Kidney-Targeted, Foundational First-Line Treatment For IgA Nephropathy FILSPARI achieved greater reductions in biomarkers linked to kidney inflammation and injury than maximum labeled dose irbesartanFindings provide further evidence of the biological effects of dual…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.
benzinga.com Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89 Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.- benzinga.com Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.
benzinga.com Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his…
benzinga.com Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $78 Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $68 to $78.
benzinga.com Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $70 Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.- benzinga.com Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $75 Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $61 to $75.
benzinga.com TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75 TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.- benzinga.com Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $85 Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $70 to $85.
- benzinga.com Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $68 Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $60 to $68.
benzinga.com Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday US stocks rise, Wynn Resorts beat earnings expectations, share price jumps 10.9%. Other companies recording gains in today's session.- benzinga.com Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $75 Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $65 to $75.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. Estrella Immunopharma…
benzinga.com Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On Travere Therapeutics shares surged 13.44% after hours as strong revenue growth and FILSPARI sales gains outweighed earnings concerns.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their…
- benzinga.com Canaccord Genuity Maintains Buy on Travere Therapeutics, Raises Price Target to $62 Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $62.
benzinga.com Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $65 Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $65.- benzinga.com Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $61 Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $55 to $61.
- benzinga.com Evercore ISI Group Maintains Outperform on Travere Therapeutics, Raises Price Target to $60 Evercore ISI Group analyst Liisa Bayko maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $52 to $60.
- benzinga.com Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $70 Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
- benzinga.com Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $65 Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $50 to $65.
- benzinga.com Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis Patients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria…
- benzinga.com Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $62 Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $59 to $62.
- benzinga.com Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $55 price target.
- benzinga.com HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $67 HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $57 to $67.
benzinga.com Travere Therapeutics Enters Into Exclusive Licensing And Collaboration Agreement With Everest Medicines For Development And Commercialization Of Civorebrutinib Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseasesCivorebrutinib adds…- benzinga.com Travere Therapeutics Receives Notice Of Allowance From U.S. Patent And Trademark Office For Patent Titled Biphenyl Sulfonamide Compounds For The Treatment Of Kidney Diseases Or Disorders Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled…
- benzinga.com Wells Fargo Maintains Overweight on Travere Therapeutics, Raises Price Target to $50 Wells Fargo analyst Mohit Bansal maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target from $40 to $50.
- benzinga.com Travere Therapeutics Plans To Offer $400M Senior Convertible Notes Due 2032 Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced its intention to offer, subject to market and other conditions, $400 million aggregate principal amount of convertible senior notes due 2032…
benzinga.com Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.- benzinga.com TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $60 TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $45 to $60.
- benzinga.com Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $59 Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $53 to $59.
- benzinga.com Wedbush Maintains Outperform on Travere Therapeutics, Raises Price Target to $55 Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $53 to $55.
- benzinga.com HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $57 HC Wainwright & Co. analyst Joseph Pantginis maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $47 to $57.
- benzinga.com Travere Therapeutics Q1 Adj. EPS $0.05 Beats $(0.26) Estimate, Sales $127.199M Miss $136.822M Estimate. Travere Therapeutics (NASDAQ:TVTX) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(0.26) by 119.23 percent. This is a 126.32 percent increase over losses…
benzinga.com Earnings Scheduled For May 4, 2026 - benzinga.com Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $56 Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $54 to $56.
- benzinga.com First FDA-Approved Treatment For Patients With Focal Segmental Glomerulosclerosis, A Rare Kidney Condition https://www.fda.gov/drugs/drug-alerts-and-statements/first-fda-approved-treatment-patients-focal-segmental-glomerulosclerosis-rare-kidney-condition
- benzinga.com Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $53 Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $48 to $53.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session